Search
Thalys Medical: Key Uncertainties Persist Regarding Success of Therapeutic Antihypertensive Vaccine Trial by Affiliated Company
1 week ago /
Read about 0 minute
Author：小编
The therapeutic antihypertensive vaccine project, HJY-ATRQβ-001, undertaken by Thalys Medical's affiliated company, Hua Ji Nian Biotechnology, has successfully concluded preclinical research and submitted an application for a new drug clinical trial (IND) to the National Medical Products Administration (NMPA) on June 6, 2025. Currently, the project stands at the conceptual verification phase, with subsequent Phase I, Phase II, and further multi-phase clinical trials on the horizon. Thalys Medical cautions investors about the considerable uncertainties surrounding the trial's success and encourages them to be mindful of associated risks and make well-informed decisions.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
